Roivant Announces Results From Its Phase 2 PHocus Clinical Trial Evaluating Mosliciguat For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; PHocus Met Its Primary Endpoint, Demonstrating Clinically Meaningful And Statistically Significant Placebo-Adjusted Reduction In Pulmonary Vascular Resistance